Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $38.0 million.

  • Ani Pharmaceuticals' Free Cash Flow rose 39532.76% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.7 million, marking a year-over-year increase of 10284.07%. This contributed to the annual value of $47.8 million for FY2024, which is 5659.86% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Free Cash Flow is $38.0 million, which was up 39532.76% from $71.8 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Free Cash Flow ranged from a high of $71.8 million in Q2 2025 and a low of -$20.9 million during Q1 2022
  • Moreover, its 5-year median value for Free Cash Flow was $13.5 million (2024), whereas its average is $13.7 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Free Cash Flow soared by 1157836.26% in 2021 and then tumbled by 175311.14% in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Free Cash Flow stood at -$12.5 million in 2021, then skyrocketed by 39.89% to -$7.5 million in 2022, then surged by 663.29% to $42.5 million in 2023, then tumbled by 68.29% to $13.5 million in 2024, then soared by 181.84% to $38.0 million in 2025.
  • Its last three reported values are $38.0 million in Q3 2025, $71.8 million for Q2 2025, and $32.5 million during Q1 2025.